Atlas Trials

Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma

6 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma

RecordFirmDate
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma (NCT06649812)National Cancer Institute (NCI)2025-10-07
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy (NCT06834373)Mayo Clinic2025-04-02
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma (NCT05821088)David Bond, MD2023-06-29
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT05507541)Mayo Clinic2023-04-19
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma (NCT05202782)Northwestern University2022-03-21
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (NCT03038672)National Cancer Institute (NCI)2018-12-21

Track Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.